A History of Innovation

Since its inception, Eurofins NTD, LLC. has demonstrated a history of innovation, beginning with its work in neural tube defect research and continuing to where it stands today, at the forefront of prenatal care and genetic screening.

1976 Eurofins NTD, LLC. founder J.N. Macri, Ph.D. introduces AFP screening for neural tube defects in the United States of America.
1983 Eurofins NTD, LLC. is founded by Dr. Macri as a prenatal screening and research laboratory.
1984 Initial observations made on the association of low AFP and Down syndrome.
1989 Initial observations made on free Beta hCG as a biomarker for Down syndrome.
1995 Eurofins NTD, LLC. introduces first trimester Down syndrome screening.
2002 Landmark NICHD study published that validates the advantages of the free Beta hCG/PAPP-A/NT protocol.
2005 Instant Risk Assessment program introduced.
2005 Fetal nasal bone assessment protocol introduced as part of the Down syndrome screening protocol.
2006 Eurofins NTD, LLC. introduces web portal to facilitate Instant Risk Assessment reporting within the Down syndrome screening protocol.
2009 Cystic Fibrosis Carrier Testing launched by Eurofins NTD, LLC.
2013 Eurofins NTD, LLC. introduces the first serum screening test for early onset preeclampsia in the U.S.
2015 Eurofins NTD, LLC. enhances it's screening protocol with the addition of alpha fetoprotein (AFP) in the first trimester to improve the detection rate of Down syndrome.
2016 Eurofins NTD, LLC. is acquired by Eurofins Scientific, click here to learn more.

DISCLAIMER: Pursuant to applicable federal and/or state laboratory requirements, Eurofins NTD, LLC has established and verified the accuracy and precision of its testing services. Tests are developed and performance characteristics determined by Eurofins NTD, LLC. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health.